Delving into the Latest Updates on 18F-LNC1007 with Synapse

Overview

Basic Info

Drug Type

Diagnostic radiopharmaceuticals

Synonyms

[18F]-LNC1007

Target

FAP x αvβ3

Mechanism

FAP modulators(Fibroblast activation protein alpha modulators), αvβ3 modulators(Integrin alpha-V/beta-3 modulators)

Therapeutic Areas

NeoplasmsOther Diseases

Active Indication

Diagnostic agentsSolid tumorNeoplasms

Inactive Indication-

Originator Organization

Yantai Lannacheng Biotechnology Co., Ltd.

Yantai Dongcheng Biochemicals Co., Ltd.

Active Organization

Yantai Lannacheng Biotechnology Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This study is a single-arm, single-center trial aimed at evaluating the pharmacokinetics, bio-distribution, dosimetry, and safety of 18F-LNC1007 injection in healthy volunteers and light tumor burden cancer patients, as defined by <5 lesions on a conventional PET/CT done for clinical purposes and molecular imaging tumor volume of <10ml.
All participants must provide a signed consent form before enrolling in the trial.
For each participant, the study duration will be about 3 weeks including 2 weeks' screening, 1 week of scanning and safety follow-up.

Start Date01 Sep 2024

Sponsor / Collaborator

Yantai Lannacheng Biotechnology Co., Ltd.

CTR20244446 / Not yet recruitingPhase 1

评价18F-LNC1007注射液在中国健康受试者中的药代动力学、生物分布和安全性的I期临床试验

[Translation] A Phase I clinical trial to evaluate the pharmacokinetics, biodistribution and safety of 18F-LNC1007 injection in healthy Chinese subjects

1)评价18F-LNC1007注射液的药代动力学特征; 2)评价18F-LNC1007注射液的生物分布和辐射剂量学; 3)初步评价18F-LNC1007注射液的安全性;

[Translation]

1) Evaluate the pharmacokinetic characteristics of 18F-LNC1007 injection; 2) Evaluate the biodistribution and radiation dosimetry of 18F-LNC1007 injection; 3) Preliminary evaluation of the safety of 18F-LNC1007 injection;

Start Date-

Sponsor / Collaborator

Yantai Lannacheng Biotechnology Co., Ltd.

100 Clinical Results associated with 18F-LNC1007

Login to view more data

100 Translational Medicine associated with 18F-LNC1007

Login to view more data

100 Patents (Medical) associated with 18F-LNC1007

Login to view more data

100 Deals associated with 18F-LNC1007

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Solid tumor	Phase 1	CN	Yantai Lannacheng Biotechnology Co., Ltd.	28 Nov 2024
Neoplasms	Phase 1	AU	Yantai Lannacheng Biotechnology Co., Ltd.	01 Sep 2024
Diagnostic agents	IND Approval	CN	Yantai Lannacheng Biotechnology Co., Ltd.	20 Sep 2024